This is the published version of a paper published in *International Journal of Cancer*.

Citation for the original published paper (version of record):

Gylling, B., Myte, R., Ulvik, A., Ueland, P M., Midttun, Ø. et al. (2019)
One-carbon metabolite ratios as functional B-vitamin markers and in relation to colorectal cancer risk
https://doi.org/10.1002/ijc.31606

Access to the published version may require subscription.

N.B. When citing this work, cite the original published paper.

Permanent link to this version:
http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-142854
One-carbon metabolite ratios as functional B-vitamin markers and in relation to colorectal cancer risk

Björn Gylling1, Robin Myte2, Arve Ulvik7, Per M. Ueland8, Øivind Midttun7, Jørn Schneede3, Göran Hallmans4, Jenny Häggström5, Ingegerd Johansson6, Bethany Van Guelpen2 and Richard Palmqvist1

1Department of Medical Biosciences, Pathology, Umeå University, Umeå, Sweden
2Department of Radiation Sciences, Oncology, Umeå University, Umeå, Sweden
3Department of Clinical Pharmacology, Pharmacology and Clinical Neurosciences, Umeå University, Umeå, Sweden
4Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, Umeå, Sweden
5Department of Statistics, Umeå School of Business and Economics, Umeå University, Umeå, Sweden
6Department of Odontology, Cariology, Umeå University, Umeå, Sweden
7Bevital AS, Laboratory building, Bergen, Norway
8Department of Clinical Science, University of Bergen and Laboratory of Clinical Biochemistry, Haukeland University Hospital, Bergen, Norway

One-carbon metabolism biomarkers are easily measured in plasma, but analyzing them one at a time in relation to disease does not take into account the interdependence of the many factors involved. The relative dynamics of major one-carbon metabolism branches can be assessed by relating the functional B-vitamin marker total homocysteine (tHcy) to transsulfuration (total cysteine) and methylation (creatinine) outputs. We validated the ratios of tHcy to total cysteine (Hcy:Cys), tHcy to creatinine (Hcy:Cre) and tHcy to cysteine to creatinine (Hcy:Cys:Cre) as functional markers of B-vitamin status. We also calculated the associations of these ratios to colorectal cancer (CRC) risk. Furthermore, the relative contribution of potential confounders to the variance of the ratio-based B-vitamin markers was calculated by linear regression in a nested case–control study of 613 CRC cases and 1,190 matched controls. Total B-vitamin status was represented by a summary score comprising Z-standardized plasma concentrations of folate, cobalamin, betaine, pyridoxal 5’-phosphate and riboflavin. Associations with CRC risk were estimated using conditional logistic regression. We found that the ratio-based B-vitamin markers all outperformed tHcy as markers of total B-vitamin status, in both CRC cases and controls. In addition, associations with CRC risk were similar for the ratio-based B-vitamin markers and total B-vitamin status (approximately 25% lower risk for high vs. low B-vitamin status). In conclusion, ratio-based B-vitamin markers were good predictors of total B-vitamin status and displayed similar associations as total B-vitamin status with CRC risk. Since tHcy and creatinine are routinely clinically analyzed, Hcy:Cre could be easily implemented in clinical practice.

Introduction
One-carbon metabolism, a complex network of enzymatic reactions using B-vitamins as co-factors and co-substrates, is important for genome stability and gene translation, and disturbances in one-carbon metabolism are associated with anemia, cardiovascular disease, tumorigenesis and other

Key words: biomarkers, colorectal cancer, biochemistry, homocysteine

Abbreviations: AUC: area under the curve; CRC: colorectal cancer; KTR: kynurenine-to-tryptophan-ratio; MSP: Mammary Screening Programme; NSHDS: Northern Sweden Health and Disease Study; OR: odds ratio; PLP: pyridoxal 5’-phosphate; ROC: receiver operating characteristic; SAM: S-adenosylmethionine; SD: standard deviation; SDMA: symmetric dimethylarginine; tHcy: total homocysteine; VIP: Västerbotten Intervention Programme

Additional Supporting Information may be found in the online version of this article.

Conflicts of interest: The authors have no conflicts of interest to declare.

Grant sponsor: Forskningsrådet för Arbetsliv och Socialvetenskap; Grant numbers: 2007-0925; Grant sponsor: Cancerfonden; Grant numbers: 12/501, 14/780; Grant sponsor: Cancer Research Foundation in Northern Sweden; Grant numbers: 15-761, 16-798, 15-768

DOI: 10.1002/ijc.31606

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

History: Received 20 Feb 2018; Accepted 17 Apr 2018; Online 22 May 2018

Correspondence to: Richard Palmqvist, Department of Medical Biosciences, Pathology; Umeå University, Umeå SE-901 85, Sweden, Tel.: 46-90-785-15-32, Fax: 46-90-12-15-62, E-mail: richard.palmqvist@umu.se
diseases. Clinically, and in medical research, plasma total homocysteine (tHcy) concentrations are used as a functional marker of B-vitamin status, in particular folate, and also other components involved in one-carbon metabolism. However, tHcy concentrations are influenced by several physiological, clinical and lifestyle factors, including age, sex, smoking, kidney function and blood pressure. Homocysteine is either metabolized through the transsulfuration pathway or remethylated into methionine. In and excess homocysteine is either metabolized through the transsulfuration pathway and SAM-dependent methylation reactions. Elevated homocysteine may be harmful to the cell, and excess homocysteine is either metabolized through the transsulfuration pathway or remethylated into methionine.

The two (Hcy:Cys:Cre), and are hereafter referred to as ratio-based biomarkers of total B-vitamin status to assess functionality and relation to CRC risk. In CRC patients and controls, the ratio-based markers outperformed tHcy as indicators of total B-vitamin status. Their association with CRC risk was similar to that of total B-vitamin status. Ratio-based biomarkers could fill a valuable role in assessments of functional B-vitamin levels and disease risk.

What’s new?
While total homocysteine (tHcy) levels are an important biomarker of B-vitamin status and may be predictive for colorectal cancer (CRC) risk, they are influenced by a variety of factors, such as age, sex, and lifestyle. Here, tHcy was compared to ratio-based biomarkers of total B-vitamin status to assess functionality and relation to CRC risk. In CRC patients and controls, the ratio-based markers outperformed tHcy as indicators of total B-vitamin status. Their association with CRC risk was similar to that of total B-vitamin status. Ratio-based biomarkers could fill a valuable role in assessments of functional B-vitamin levels and disease risk.

Materials and Methods
Study participants
This was a case-control study nested within the Northern Sweden Health and Disease Study (NSHDS). Participants from two population-based subcohorts were included, the Västerbotten Intervention Programme (VIP, 78% of the study participants) and the Mammography Screening Project in Västerbotten (MSP, 22% of the study participants). In the VIP, established in 1985, residents of Västerbotten County are invited to
participate in a health survey upon turning 30 (years 1990–1996), 40, 50 and 60 years of age. The health survey consists of laboratory tests and a medical examination, donation of a fasting blood sample and completion of an extensive lifestyle questionnaire. The VIP included 115,147 blood samples from 85,877 individuals as of March 31, 2009, the final date for case identification for our study (Supporting Information Fig. S1). Selection bias has been found to be low, and comparisons of cancer incidence in the cohort with expected incidence (based on data from the Swedish Cancer Registry) support the population-based structure of the VIP cohort. The MSP was established in 1995 and concluded in 2006, and invited women residing in Västerbotten County and about 50–70 years of age, to complete a lifestyle questionnaire and donate a blood sample while attending mammography screening. The MSP includes a total of 54,401 blood samples from 28,802 women.

CRC case participants diagnosed between October 17, 1986, and March 31, 2009, were identified by linkage with the essentially complete Cancer Registry of Northern Sweden (ICD-10 C18.0 and C18.2–C18.9 for colon, C19.9 and C20.9 for rectum). A single pathologist specialized in gastrointestinal pathology verified all cases and tumor data. Patient records were used to verify tumor site. Exclusion criteria were previous cancer diagnosis other than non-melanoma skin cancer (68 cases), insufficient volume of stored plasma samples (46 cases, nine controls), location of the primary tumor outside of the colorectum (18 cases), samples prioritized to other studies (eight cases, 18 controls), serious infectious disease (one case, excluded for the safety of the laboratory staff) or no matching control available (three cases).

Two control participants were randomly selected for each case, matched by age at and year of blood sampling and data collection, cohort, sex and fasting status. The same exclusion criteria were applied to the control participants as the case participants. Furthermore, controls were all alive and had no diagnosed cancer other than non-melanoma skin cancer at the time of diagnosis of their index cases. After exclusions (81 cases and 18 controls), 613 cases and 1,190 controls were included for data analyses (Supporting Information Fig. S1).

The data handling procedures and study protocol were approved by the Research Ethics Committee of Umeå University, Umeå, Sweden (Dnr 03-186). All participants gave a written informed consent at the time of recruitment to the cohorts. All data and samples were de-identified.

**Blood sampling and analysis**

The blood samples for our study were collected in EDTA sample tubes, separated into plasma, erythrocyte fractions and buffy coat and cryopreserved at −80°C at a central location. Samples were frozen within 1 hr of collection, either at −80°C or at −20°C for up to 1 week before transfer to a −80°C freezer. In the VIP samples are collected in the morning, and only 2% had fasted <4 hr, and 21% <8 hr. In the MSP, blood samples were collected throughout the day, and 96% had fasted for <4 hr.

All biochemical analyses were performed at Bevital A/S (http://www.bevital.no), Bergen, Norway, in 2011. Plasma concentrations of betaine, riboflavin, creatine, neopterin, symmetric dimethylarginine (SDMA) and PLP were measured with liquid chromatography–mass spectrometry methods (between-day coefficient of variation (CV): 3–13%). Plasma concentrations of tHcy, tCys, kynurenine and tryptophan were measured using an isotope dilution gas chromatography–mass spectrometry method (between-day CV: 2–9%). Folate and cobalamin concentrations were determined by a microbiological method using *Lactobacillus casei* and *Lactobacillus leichmannii*, respectively, adapted to a microtiter plate format and carried out by a robotic workstation (between-day CV: 5%), MTHFR rs1801133 genotype was determined using MALDI-TOF mass spectrometry (estimated average error rate of ≤0.1% in duplicated samples). The investigators and laboratory staff were blinded to case and control status.

**Statistical analyses**

All computations were conducted in R v.3.3.2 (R Foundation for Statistical Computing, Vienna, Austria). All tests were two-sided, and *p*-values < 0.05 were considered statistically significant. Mann–Whitney *U*-test or *χ*-test were used to test for univariate differences in variable distributions between groups.

We calculated total B-vitamin status score by summing log-transformed and standardized (z = x-mean/standard deviation (SD)) plasma concentrations of folate, cobalamin, betaine, PLP and riboflavin. The influence of the B-vitamin score and other variables on tHcy and B-vitamin markers was then evaluated in multiple linear regression models. The relative contribution to total explained variance (R²) for tHcy and B-vitamin markers were assessed using the lmg algorithm in the relaimbo R package. The lmg algorithm decomposes total R² into a contribution for each predictor in a regression model by taking the average R² contribution of each predictor over all possible model sizes and predictor combinations. Four linear regression models were fitted, with log-transformed standardized tHcy, Hcy:Cys, Hcy:Crem and Hcy:Cys:Cre as response variables, and sex, age, cohort (VIP or MSP), fasting status (<4 hr, 4–8 hr, ≥8 hr), sample year, smoking status (non-, current-, former-smoker), BMI, kynurenine-to-tryptophan-ratio (KTR), neopterin, SDMA and B-vitamin score as predictor variables. We also evaluated the contribution of individual B-vitamins by estimating the same models but with log-transformed standardized B-vitamins included as separate variables. To compare associations between B-vitamin score and ratio-based B-vitamin markers, we evaluated regression-based sensitivity (defined as B-vitamin marker variance explained by B-vitamin score), regression-based specificity (defined as B-vitamin marker variance explained by B-vitamin score divided by total variance explained) and performance (defined as sensitivity multiplied by specificity). In addition, we also calculated more clinically applied metrics, i.e., diagnostic sensitivity, specificity and area under the curve (AUC) for Statistical Cancer Epidemiology.
Functional B-vitamin markers and CRC risk

The interaction between MTHFR rs1801133 genotype and biomarkers were tested using a likelihood ratio test comparing the interaction model to a model with a main effects model without interaction term. Heterogeneity of the risk associations by tumor subgroups was tested with likelihood ratio tests, comparing a model in which the risk association could vary across subgroups to a model in which all associations were held constant.42

**Results**

**Baseline characteristics**

The study cohort consisted of 41% males with a median age of approximately 60 years, most of whom were from the VIP cohort (78%) (Table 1). About 20% of both cases and controls were current smokers, whereas the frequency of former smokers was slightly higher in cases (p = 0.01). Baseline data for BMI, physical activity (occupational and recreational), alcohol intake and dietary fibre intake were comparable for cases and controls. Of the B-vitamins, plasma concentrations of cobalamin, betaine and riboflavin were significantly lower in cases than in controls, and, consequently, the total B-vitamin score was also significantly lower in cases than in controls. Plasma concentrations of the inflammatory marker neopterin were significantly higher in CRC cases than in controls. Of the ratio-based B-vitamin markers, Hcy:Cys was significantly higher in CRC cases than in controls. The median age at diagnosis for CRC cases was 65.2 years (5th–95th percentile: 50.3–76.2 years), and the median follow-up time was 8.2 years from sampling to diagnosis. The CRC cases were approximately equally distributed with respect to tumor location in the right colon (30%), left colon (35%) and rectum (35%), as well as tumor stage (53% stages I–II, 47% stages III–IV).

**Associations between B-vitamin markers and B-vitamin score**

The predictors (sex, age, cohort, fasting status, smoking, BMI, KTR, neopterin, SDMA and total B-vitamin score) explained about one-third of the variance of tHcy and the ratio-based B-vitamin markers in both cases and controls (Fig. 1). Although contributions to explained variance were slightly higher in cases for some variables (total B-vitamin score and neopterin), there were overall no large differences in between cases and controls. As expected, total B-vitamin score had the strongest association with tHcy and the ratio-based B-vitamin markers (inverse association). Regression-based sensitivity (defined as variance explained by total B-vitamin score) and specificity (defined as variance explained by B-vitamin score divided by total variance explained by model) were 16.6 and 55.9% for tHcy, 23.5 and 72.7% for Hcy:Cys, 21.5 and 73.7% for Hcy:Cre and 27.0 and 83.3% for Hcy:Cys:Cre, respectively, in controls and similar in cases (Table 2). Thus, overall performance (sensitivity multiplied by specificity) was better for the ratio-based B-vitamin markers compared to tHcy (performances: 9.3, 17.1, 15.8 and 22.5 for tHcy, Hcy:Cys, Hcy:Cre and Hcy:Cys:Cre, respectively, in controls). In models with separate B-vitamins as predictors, folate was the strongest contributor for all ratio-based B-vitamin markers (explaining 10–15% of the variance for tHcy and the ratio-based B-vitamin markers), followed by cobalamin, betaine, PLP and riboflavin (each explaining 1–10% of variance) in controls. No other predictors explained >5% of the total variation for tHcy or the ratio-based B-vitamin markers, including markers of kidney function or inflammation.

Regression-based sensitivity, specificity and performance were higher for both tHcy and the ratio-based B-vitamin markers in participants with the homozygous variant MTHFR rs1801133 (TT) genotype (Supporting Information Fig. S2, Table S1). However, differences by genotype were smaller for the ratios, in particular, ratios with Hcy:Cys and Hcy:Cys:Cre, for which performance was above 15 for all genotypes.

In the ROC analysis, results consistent with the regression-based analyses were observed (Fig. 2). The ratio-based B-vitamin
Table 1. Baseline and colorectal cancer case characteristics

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Cases (n = 613)</th>
<th>Controls (n = 1,190)</th>
<th>p²</th>
</tr>
</thead>
<tbody>
<tr>
<td>VIP cohort, n (%)</td>
<td>479 (78)</td>
<td>951 (78)</td>
<td></td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>253 (41)</td>
<td>487 (41)</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td>59.8 (50.1–60.1)</td>
<td>59.7 (50.1–60.1)</td>
<td></td>
</tr>
<tr>
<td>Fasting ≥8 hr, n (%)</td>
<td>365 (60)</td>
<td>716 (60)</td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>25.7 (23.5–28.2)</td>
<td>25.6 (23.2–28.1)</td>
<td>0.43</td>
</tr>
<tr>
<td>Smoking status, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>114 (19)</td>
<td>239 (20)</td>
<td>0.01</td>
</tr>
<tr>
<td>Former smoker</td>
<td>136 (22)</td>
<td>197 (17)</td>
<td></td>
</tr>
<tr>
<td>No recreational physical activity, n (%)³</td>
<td>211 (45)</td>
<td>354 (40)</td>
<td>0.39</td>
</tr>
<tr>
<td>Sedentary or standing work, n (%)³</td>
<td>90 (22)</td>
<td>163 (20)</td>
<td>0.21</td>
</tr>
<tr>
<td>Alcohol intake, g/day³⁴</td>
<td>2.4 (0.2–5.8)</td>
<td>2.3 (0.3–5.7)</td>
<td>0.94</td>
</tr>
<tr>
<td>Dietary fiber intake, g/2,000 kcal³⁴</td>
<td>22.4 (18.5–26.7)</td>
<td>22.7 (18.5–26.3)</td>
<td>0.93</td>
</tr>
<tr>
<td>eGFR, mL/min/1.73m²</td>
<td>61.9 (52.3–73.0)</td>
<td>61.7 (50.9–72.3)</td>
<td>0.48</td>
</tr>
<tr>
<td>SDMA, μmol/L</td>
<td>0.65 (0.55–0.75)</td>
<td>0.64 (0.56–0.75)</td>
<td>0.73</td>
</tr>
<tr>
<td>Creatinine, μmol/L</td>
<td>65.1 (57.2–73.5)</td>
<td>64.9 (57.4–72.9)</td>
<td>0.78</td>
</tr>
<tr>
<td>fHcy, μmol/L</td>
<td>10.1 (8.4–11.9)</td>
<td>9.9 (8.2–11.7)</td>
<td>0.15</td>
</tr>
<tr>
<td>Cysteine, μmol/L</td>
<td>275 (253–299)</td>
<td>276 (255–298)</td>
<td>0.74</td>
</tr>
<tr>
<td>B-vitamins</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Folate, nmol/L</td>
<td>7.25 (4.89–10.37)</td>
<td>7.15 (4.60–10.24)</td>
<td>0.49</td>
</tr>
<tr>
<td>Cobalamin, pmol/L</td>
<td>413 (337–498)</td>
<td>426 (353–510)</td>
<td>0.02</td>
</tr>
<tr>
<td>Betaine, μmol/L</td>
<td>29.9 (25.7–34.4)</td>
<td>30.8 (26.1–35.5)</td>
<td>0.05</td>
</tr>
<tr>
<td>Riboflavin, nmol/L</td>
<td>10.8 (7.4–16.0)</td>
<td>11.8 (7.9–17.9)</td>
<td>0.002</td>
</tr>
<tr>
<td>PLP, nmol/L</td>
<td>35.9 (25.9–51.5)</td>
<td>38.2 (28.0–51.5)</td>
<td>0.08</td>
</tr>
<tr>
<td>B-vitamin score</td>
<td>-0.48 (-1.95 to 1.54)</td>
<td>-0.00 (-1.73 to 1.69)</td>
<td>0.05</td>
</tr>
<tr>
<td>Ratio-based B-vitamin markers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>fHcy:Cys (×100)</td>
<td>3.65 (3.15–4.23)</td>
<td>3.57 (3.05–4.17)</td>
<td>0.05</td>
</tr>
<tr>
<td>fHcy:Cys (×100)</td>
<td>15.3 (12.9–18.4)</td>
<td>15.1 (12.6–18.8)</td>
<td>0.29</td>
</tr>
<tr>
<td>Hcy:Cys:Cre (×10,000)</td>
<td>5.59 (4.75–6.64)</td>
<td>5.47 (4.66–6.61)</td>
<td>0.25</td>
</tr>
<tr>
<td>Inflammatory markers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KTR (×1,000)</td>
<td>22.5 (19.4–26.0)</td>
<td>22.1 (19.3–25.7)</td>
<td>0.23</td>
</tr>
<tr>
<td>Neopterin, nmol/L</td>
<td>9.69 (8.21–11.90)</td>
<td>9.36 (7.95–11.36)</td>
<td>0.01</td>
</tr>
<tr>
<td>MTHFR rs1801133 genotype, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CC</td>
<td>326 (53)</td>
<td>580 (49)</td>
<td>0.23</td>
</tr>
<tr>
<td>CT</td>
<td>232 (38)</td>
<td>489 (41)</td>
<td></td>
</tr>
<tr>
<td>TT</td>
<td>53 (9)</td>
<td>112 (9)</td>
<td></td>
</tr>
<tr>
<td>Case characteristics</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age at diagnosis, years</td>
<td>65.2 (59.3–70.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Follow-up time, years</td>
<td>8.2 (4.7–11.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tumor site, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right colon</td>
<td>183 (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left colon</td>
<td>215 (35)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rectum</td>
<td>214 (35)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continues)
markers, of which Hcy:Cys:Cre performed best, were better than tHcy at predicting low total B-vitamin score (AUC 0.75–0.80 for B-vitamin markers, 0.70 for tHcy in controls). AUCs were slightly higher in cases, as in the linear regression analyses (data not shown). The ratio-based B-vitamin markers were weaker predictors of kidney dysfunction/inflammation (AUCs 0.50–0.62) than tHcy (AUC 0.68), again confirming the specificity of the ratios as markers of total B-vitamin status observed in the regression-based analyses.

Table 1. Continued

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Cases (n = 613)</th>
<th>Controls (n = 1,190)</th>
<th>p²</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tumor stage, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>308 (53)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III–IV</td>
<td>276 (47)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: VIP: Västerbotten intervention programme; BMI: body mass index; eGFR: estimated glomerular filtration rate; SDMA: symmetric dimethylarginine; tHcy: total homocysteine; PLP: pyridoxal 5'-phosphate; KTR: kynurenine-to-tryptophan ratio (given as kynurenine (nmol/L) divided by tryptophan (μmol/L)); MTHFR: methylenetetrahydrofolate reductase.

1Plasma biomarker levels are described in medians (25th–75th percentile).
2From test for difference in variable distribution between cases and controls. Mann–Whitney U-tests for continuous variables, χ² tests for categorical variables. Not conducted for case–control matching variables.
3Variables only available in the VIP cohort.
4Estimated from self-administered, semi-quantitative food frequency questionnaires (FFQs) designed to measure intakes from the previous year in mass/day.

Table 2. Performance of total B-vitamin score in predicting plasma tHcy, Hcy:Cys, Hcy:Cre and Hcy:Cys:Cre status in CRC cases and controls

<table>
<thead>
<tr>
<th></th>
<th>tHcy</th>
<th>Hcy:Cys</th>
<th>Hcy:Cre</th>
<th>Hcy:Cys:Cre</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity, %</td>
<td>Specificity, %</td>
<td>Performance</td>
<td>Performance</td>
</tr>
<tr>
<td></td>
<td>Cases</td>
<td>Controls</td>
<td>Cases</td>
<td>Controls</td>
</tr>
<tr>
<td></td>
<td>16.7</td>
<td>16.6</td>
<td>26</td>
<td>23.5</td>
</tr>
<tr>
<td></td>
<td>55.6</td>
<td>55.9</td>
<td>75.1</td>
<td>72.7</td>
</tr>
<tr>
<td></td>
<td>9.3</td>
<td>9.3</td>
<td>19.5</td>
<td>17.1</td>
</tr>
<tr>
<td></td>
<td>1 (ref)</td>
<td>1 (ref)</td>
<td>2.1</td>
<td>1.8</td>
</tr>
<tr>
<td></td>
<td>3.0</td>
<td>2.4</td>
<td>28.2</td>
<td>22.5</td>
</tr>
</tbody>
</table>

1Defined as sensitivity explained by B-vitamin score.
2Defined as specificity explained by B-vitamin score divided by total variance explained by the model.
3Sensitivity multiplied by specificity divided by 100.
Associations between B-vitamin markers and CRC risk

ORs for CRC risk by tertiles (categorical) and per standard deviation (SD, continuous) increase in B-vitamin score, and decrease in Hcy:Cys, Hcy:Cre and Hcy:Cys:Cre, are shown in Figure 3. Higher B-vitamin status was associated with a reduced risk of CRC, independently of the observed potential confounders. The negative association for total B-vitamin score was not weakened by the removal of folate from the B-vitamin score calculation (Supporting Information Fig. S3). Associations for ratio-based B-vitamin markers were similar.
to those for the B-vitamin score. None of the ratio-based marker ORs differed significantly from each other in z-tests based on the estimated standardized regression coefficients and covariance matrices (all \( p > 0.25 \)). tHcy, cysteine or creatinine included as separate variables were not associated with CRC risk, regardless of whether the variables were mutually adjusted for each other or not (ORs: 0.85–0.90, all \( p > 0.30 \), data not shown). We observed no large differences with respect to follow-up time between sampling and diagnosis (\( \phi_{\text{heterogeneity}} = 0.15–0.76 \), data not shown).

Next, we evaluated interactions between MTHFR rs1801133 genotype and the total B-vitamin score and the ratio-based B-vitamin markers. Homozygous or heterozygous variant genotypes are weakly associated with a reduced CRC risk in this cohort, as previously reported.\(^{19} \) The group with common homozygous rs1801133 genotype in combination with low B-vitamin status as estimated by total B-vitamin score or the ratio-based markers, had the highest CRC risk in all interaction models. However, there was no multiplicative increase in CRC risk in participants with both homozygous or heterozygous variant rs1801133 genotypes and high B-vitamin status (\( \phi_{\text{interaction}} = 0.16 \) to 0.76, Supporting Information Fig. S4).

**Discussion**

We evaluated ratios of metabolites (Hcy:Cys, Hcy:Cre and Hcy:Cys:Cre) as functional ratio-based markers of total B-vitamin status in a nested case–control study of 613 CRC cases and 1,190 matched control participants from the population-based cohorts of the NSHDS. Compared to tHcy, the three ratio-based B-vitamin markers explained a greater portion of the total B-vitamin score in both case and control participants. Furthermore, similar to the total B-vitamin status, B-vitamin status as estimated by the ratio-based B-vitamin markers was also inversely associated with CRC risk.

Our investigation validates the performance of the ratio-based B-vitamin markers previously observed in two Norwegian cohorts of patients with suspected stable angina pectoris.\(^{15} \) Now, for the first time, we demonstrate the utility of these ratio-based B-vitamin markers in a general population-based sample. Nutritional, the main difference in metabolite concentrations between the Norwegian cohorts and the NSHDS is the lower median folate concentrations in the NSHDS. Folate and cobalamin are both important determinants of tHcy concentrations, especially at lower total concentrations of B-vitamins.\(^{8,43} \)

Ratio-based markers minimize influences from shared determinants (e.g., kidney dysfunction being associated with both plasma concentrations of tHcy and creatinine), and the ratio-based B-vitamin markers were not influenced by common confounders such as kidney function, smoking and inflammation. Moreover, the ratio-based B-vitamin markers performed equally well in healthy controls and in participants who later developed CRC. Hcy:Cys:Cre had the highest sensitivity and specificity as a functional marker of total B-vitamin status. However, both Hcy:Cys and Hcy:Cre performed significantly better than tHcy alone, and both plasma concentrations of tHcy and creatinine are simple and cost-efficient markers already routinely analyzed in clinical practice. The metabolite ratio of urine albumin:creatinine is recommended in clinical and laboratory guidelines for the definition of chronic kidney disease, and has been observed in population studies to accurately predict cardiovascular risks.\(^{44} \) Similarly, Hcy:Cre would be easy to implement in clinical practice as a routine output in clinical chemistry reports to aid interpretation of test results, and could provide additional information in investigations of one-carbon metabolism in disease risk. Hcy:Cys and Hcy:Cys:Cre also show promise as biomarkers of total B-vitamin status, but the necessary component cysteine is not commonly analyzed in clinical practice.

In our study, the functional ratio-based markers give new important insights into the relationship between one-carbon metabolites and CRC risk. Low circulating folate levels are associated with lower CRC risk in our cohort,\(^{24,28} \) as well as in a previous study of a population with similar low folate status.\(^{27} \) In our study, folate is the main factor explaining variation in the ratio-based B-vitamin markers, yet higher B-vitamin status estimated with the ratio-based B-vitamin markers or the total B-vitamin score (with or without folate) demonstrated linear inverse associations with CRC risk. This indicates that the higher risk associated with higher folate in a population with low folate status could be attenuated by an adequate supply of other one-carbon metabolites. Cobalamin appears to be almost as important as folate in explaining variations in the ratio-based B-vitamin markers, and it has been suggested that vitamin B-12 should accompany folic acid in mandatory fortification programs.\(^{45} \)

Strengths of our study include high-quality prediagnostic blood samples with respect to the fasting status and sample collection, handling and storage (low-preanalytical variability). The NSHDS population is characterized by a general low folate status,\(^{46–48} \) giving us the opportunity to study one-carbon metabolism in a population with a high portion of total folate intake derived from naturally occurring folates. However, results based on the NSHDS, may not be generalized to other cohorts and populations subject to folic acid fortification. We used a total B-vitamin score comprising of standardized concentrations of betaine, riboflavin, PLP, folate and cobalamin, whereas a B-vitamin score without betaine has previously been used to estimate general B-vitamin status.\(^{46} \) Betaine was included in the score in the present work because it is an important methyl donor associated with tHcy concentrations, particularly in individuals with the variant MTHFR rs1801133 genotype and/or poor folate status.\(^{49} \) A weakness in the ROC analysis was the definition of low total B-vitamin status as the lowest fifth percentile of the total B-vitamin score distribution. Participants in this group may not have a
References


